Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lupin Inks Licensing Deal to Supply Biosimilar Ranibizumab in Latin America
Details : SteinCares will handle all regulatory filings, registrations and commercialisation of LUBT010 (ranibizumab) in Latin America, while Lupin will be responsible for manufacturing the same.
Product Name : LUBT010
Product Type : Antibody
Upfront Cash : Undisclosed
May 26, 2025
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement